WO2003040333A3 - Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof - Google Patents

Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof Download PDF

Info

Publication number
WO2003040333A3
WO2003040333A3 PCT/US2002/035588 US0235588W WO03040333A3 WO 2003040333 A3 WO2003040333 A3 WO 2003040333A3 US 0235588 W US0235588 W US 0235588W WO 03040333 A3 WO03040333 A3 WO 03040333A3
Authority
WO
WIPO (PCT)
Prior art keywords
present
methods
nrs1
protein
astrocytes
Prior art date
Application number
PCT/US2002/035588
Other languages
French (fr)
Other versions
WO2003040333A2 (en
Inventor
David E Weinstein
Carlos Suarez
Marielba Zerlin
Original Assignee
Einstein Coll Med
David E Weinstein
Carlos Suarez
Marielba Zerlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Einstein Coll Med, David E Weinstein, Carlos Suarez, Marielba Zerlin filed Critical Einstein Coll Med
Priority to AU2002363524A priority Critical patent/AU2002363524B2/en
Priority to EP02802862A priority patent/EP1578915A4/en
Priority to JP2003542580A priority patent/JP4503287B2/en
Priority to CA002466334A priority patent/CA2466334A1/en
Priority to NZ532989A priority patent/NZ532989A/en
Publication of WO2003040333A2 publication Critical patent/WO2003040333A2/en
Publication of WO2003040333A3 publication Critical patent/WO2003040333A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)

Abstract

The present invention provides methods for inhibiting proliferation of astrocytes and astrocytic tumor cells. The present invention further provides methods for treating a condition associated with a defect in astrocyte proliferation in a subject, and methods for treating a condition associated with astrocytic tumor cell proliferation in a subject. Additionally, the present invention discloses methods for enhancing survival of neurons. The present invention still further provides methods for treating neural degeneration in a subject. The present invention is also directed to pharmaceutical compositions, comprising NrS1 protein or nucleic acid and a pharmaceutically-acceptable carrier. Finally, the present invention provides a purified NrS1 protein, an agent that binds to the NrS1 protein, a kit comprising an agent that binds to the NrS1 protein, and a composition comprising the NrS1 protein and a carrier.
PCT/US2002/035588 2001-11-07 2002-11-07 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof WO2003040333A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2002363524A AU2002363524B2 (en) 2001-11-07 2002-11-07 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
EP02802862A EP1578915A4 (en) 2001-11-07 2002-11-07 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
JP2003542580A JP4503287B2 (en) 2001-11-07 2002-11-07 Methods for inhibiting the growth of astrocytes and astrocyte tumor cells, methods for increasing neuronal survival, and uses thereof
CA002466334A CA2466334A1 (en) 2001-11-07 2002-11-07 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
NZ532989A NZ532989A (en) 2001-11-07 2002-11-07 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34471201P 2001-11-07 2001-11-07
US60/344,712 2001-11-07

Publications (2)

Publication Number Publication Date
WO2003040333A2 WO2003040333A2 (en) 2003-05-15
WO2003040333A3 true WO2003040333A3 (en) 2006-04-27

Family

ID=23351677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035588 WO2003040333A2 (en) 2001-11-07 2002-11-07 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof

Country Status (6)

Country Link
EP (1) EP1578915A4 (en)
JP (1) JP4503287B2 (en)
AU (1) AU2002363524B2 (en)
CA (1) CA2466334A1 (en)
NZ (1) NZ532989A (en)
WO (1) WO2003040333A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087882A2 (en) * 2003-03-26 2004-10-14 Washington University Neuregulin protein regulation of synaptic proteins
EP1570857A1 (en) * 2004-02-27 2005-09-07 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for inhibiting the transendothelal migration of cells such as leukocytes or tumor cells by a CD81 binding agent and uses thereof
JP6861349B2 (en) * 2015-09-15 2021-04-21 中西　徹 CD81 LEL-specific monoclonal antibody

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CLARKE K. ET AL: "The Target of the Antiproliferative Antibody (TAPA) in the Normal and Injured Rat Retina", MOL VISION, vol. 4, February 1998 (1998-02-01), pages 3 - 8, XP002995977 *
DIJKSTRA S.: "CD81 and Microglial Activation in Vitro: Proliferation, Phagocytosis and Nitric Oxide Production", J. NEUROIMMUNOL, vol. 114, March 2001 (2001-03-01), pages 151 - 159, XP001206095 *
GEISERT E.E. JR. ET AL: "Astrocyte Growth, Reactivity, and the Target of the Antiproliferative Antibody, TAPA", J. NEUROSCIENCE, vol. 16, no. 17, September 1996 (1996-09-01), pages 5478 - 5487, XP002951198 *
KELIC S. ET AL: "CD81 Regulates Neuron-Induced Astrocyte Cell-Cycle Exit", MOLL CELL NEUROSCI, vol. 17, March 2001 (2001-03-01), pages 551 - 560, XP002951199 *
See also references of EP1578915A4 *
STIPP C.S. ET AL: "Transmembrane-4-superfamily Proteins CD151 and CD81 Associate with alpha-3-beta-1 Integrin, and Selectively Contribute to alpha-3-beta-1-Dependent Neurite Outgrowth", J. CELL SCIENCE, vol. 113, June 2000 (2000-06-01), pages 1871 - 1882, XP002995976 *
YUNTA M. ET AL: "Tetraspanin Proteins as Organisers of Membrane Microdomains and Signalling Complexes", CELLULAR SIGNALING, vol. 15, June 2003 (2003-06-01), pages 559 - 564, XP002995978 *

Also Published As

Publication number Publication date
JP4503287B2 (en) 2010-07-14
JP2005537779A (en) 2005-12-15
NZ532989A (en) 2009-04-30
EP1578915A2 (en) 2005-09-28
EP1578915A4 (en) 2008-02-13
AU2002363524B2 (en) 2008-12-04
WO2003040333A2 (en) 2003-05-15
CA2466334A1 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
PT1053256E (en) Antibodies to death receptor 4 (dr4) and uses thereof
BRPI0412845A (en) herpes virus, use of a virus, pharmaceutical composition, and method of treating a tumor in an individual in need thereof
WO2003066661A3 (en) Human dr4 antibodies and uses thereof
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
IL127558A0 (en) Hepatocyte growth factor receptor agonists and uses thereof
WO2004011611A3 (en) Taci antibodies and uses thereof
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
WO2008060813A3 (en) High affinity antibody antagonists of interleukin-13 receptor alpha 1
EP2281578A3 (en) Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
WO2004048551A3 (en) Target for therapy of cognitive impairment
IL146448A0 (en) Dr4 antibodies and uses thereof
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
WO2003040333A3 (en) Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
MXPA02000680A (en) Vgf polypeptides and methods of treating vgf-related disorders.
WO2003076610A3 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
EP2116616A3 (en) Genes differentially expressed in activated T cells and uses thereof
WO2005110460A3 (en) Diagnosis and treatment methods related to aging, especially in muscle (14.1)
EP1038524A4 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
WO2005039488A3 (en) Use of cxcr4 protein expression on the surface of stem cells as a marker for tumor tropic potential
WO2000078803A3 (en) Use of eif4e binding agents in therapy
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2466334

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003542580

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 532989

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002802862

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002363524

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1409/DELNP/2004

Country of ref document: IN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002802862

Country of ref document: EP